Bayer NDA Filing For Renal Cancer Agent May Be Based On Phase II Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer may submit an NDA for its Raf kinase inhibitor BAY 43-9006 using Phase II data in renal carcinoma, Bayer Health Care Chairman Arthur Higgins said.